Collins Helen Louise 4

What Happened

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), reported option exercise(s) and open-market sales on May 18, 2026. She exercised options to acquire 5,000 shares at $2.48 per share (cash cost $12,400). The filing also reports a derivative conversion/settlement of 5,000 shares (reported with $0 cash consideration).
• On the same date she sold a total of 5,000 shares in three open-market transactions for aggregate proceeds of approximately $198,972 (individual weighted-average prices: 3,475 shares @ $39.53 = $137,381; 1,302 shares @ $40.25 = $52,402; 223 shares @ $41.21 = $9,189).

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (filed two days after trades).
• Sales executed in multiple trades with price ranges reported: $38.855–$39.85; $39.855–$40.83; $40.8625–$41.605 (weighted averages reported above).
• Total proceeds from sales: ~$198,972. Total cash paid to exercise options reported: $12,400.
• Footnotes: Sales were made pursuant to a Rule 10b5-1 trading plan adopted Oct 19, 2025. Some reported securities are RSUs (each RSU = contingent right to one share). All shares subject to the option were fully vested as of the date of exercise.
• Shares owned after the transactions are not specified in the information provided on this Form 4.

Context

• The filing shows a same-day exercise/derivative conversion and open-market sales. That pattern can reflect an option exercise followed by sales (often implemented via a Rule 10b5-1 plan); this description is procedural and not a statement about Collins’ view of the company.
• RSU settlements and option exercises are common forms of executive compensation and may be sold to cover taxes or diversify holdings; retail investors should treat such filings as factual disclosures rather than direct indicators of management sentiment.